Loading
This study tests a PARP inhibitor; the registry reports that it is recruiting.
The registry lists NCT05797168 as recruiting, last updated 2026-10-05. Enrolment is 622 planned participants, an estimate. Interventions: Torvutatug samrotecan, Saruparib, Bevacizumab, Carboplatin, Palacaparib, Pembrolizumab. Primary measures include Number of participants with adverse events/serious adverse events; The number of participants with dose limiting toxicity(DLT), as defined in the protocol. No results are posted in the registry; this does not exclude separate publications.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Palacaparib, Saruparib, PARP, Endometrial cancer.
Shares AZD5335, AstraZeneca, Ovarian cancer.
Shares Palacaparib, PARP, AstraZeneca.
Shares Saruparib, PARP, Ovarian cancer.
Shares Saruparib, PARP, AstraZeneca.
Shares Saruparib, PARP, AstraZeneca, Carboplatin.
Shares Saruparib, PARP, AstraZeneca.
Shares Saruparib, PARP, AstraZeneca.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/